AI assistant
Sending…
Lexaria Bioscience Corp. — Director's Dealing 2021
Sep 2, 2021
34983_dirs_2021-09-02_de91a03f-4283-45f2-8219-885a93705219.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Lexaria Bioscience Corp. (LEXX)
CIK: 0001348362
Period of Report: 2021-09-01
Reporting Person: McKechnie William Edward (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-09-01 | Stock Options | $6.23 | A | 1900 | Acquired | 2026-09-01 | Common Shares (1900) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| common shares | 13191 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Options | $5.31 | 2026-04-26 | Common Shares (1500) | 1500 | Direct |
| Stock Options | $7.08 | 2026-06-08 | Common Shares (5000) | 6500 | Direct |
More from Lexaria Bioscience Corp.
Interim / Quarterly Report
2026
Apr 13
Director's Dealing
2026
Mar 18
Delisting Announcement
2026
Feb 6
Regulatory Filings
2026
Jan 28
Declaration of Voting Results & Voting Rights Announcements
2026
Jan 28
Capital/Financing Update
2026
Jan 14
Delisting Announcement
2026
Jan 14
Interim / Quarterly Report
2026
Jan 13
Capital/Financing Update
2025
Dec 29
Regulatory Filings
2025
Dec 19